By Alex Vadukul Eli Zabar, the longtime king of a Manhattan food and delicatessen empire, teamed up with the online newsletter platform Substack on Tuesday night to celebrate the 50th anniversary ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They discuss the challenges of developing products that counter diseases and ...

Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and obese or overweight people over 176 weeks; shares rose modestly after ...

Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its ...

Wolfe Research initiated coverage of Eli Lilly (LLY) with an Outperform rating and $1,000 price target The company has lost over $100B in market cap over the past few weeks, creating an attractive ...

The Los Angeles Chargers today elevated cornerback Eli Apple and outside linebacker Caleb Murphy from the practice squad for Sunday's game. Apple was elevated for each of the last two weeks, posting a ...

Energy Minister Eli Cohen (Likud) told Reuters on Thursday. Cohen noted that President-elect Donald Trump’s appointees are poised to support a strong policy against Iran. "The period of Trump ...

RISES OVER 1.6% AT IT’S HIGH FOR THE DAY AFTER EARLY DROP AND THE POWER INFLOW SIGNAL Eli Lilly & Company LLY today experienced a Power Inflow, a significant event for those who follow where ...

Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair and CEO Dave Ricks. They discuss the challenges of developing products that counter diseases and ...

INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...